KR20050044365A - Igg 항체의 안정한 액상 약학 제형물 - Google Patents
Igg 항체의 안정한 액상 약학 제형물 Download PDFInfo
- Publication number
- KR20050044365A KR20050044365A KR1020047006962A KR20047006962A KR20050044365A KR 20050044365 A KR20050044365 A KR 20050044365A KR 1020047006962 A KR1020047006962 A KR 1020047006962A KR 20047006962 A KR20047006962 A KR 20047006962A KR 20050044365 A KR20050044365 A KR 20050044365A
- Authority
- KR
- South Korea
- Prior art keywords
- antibody
- formulation
- buffer
- liquid pharmaceutical
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/246—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Abstract
Description
Na-숙시네이트(pH6.0) 및 Na-포스페이트(pH6.5) 완충액 중에서 5 및 45℃에서 T=0 및 T=4주에 형광 조명으로 결정된 시료의 투명도 | ||||||
시료 | 포스페이트T=0투명도 | 포스페이트T=3 주투명도, 5℃ | 포스페이트T=3 주투명도,45℃ | 숙시네이트T=0투명도 | 숙시네이트T=3 주투명도, 5℃ | 숙시네이트T=3 주투명도,45℃ |
Tween-80 | 투명 | 투명 | 투명 | 투명 | 투명 | 투명 |
EDTA | 투명 | 투명 | 투명 | 투명 | 투명 | 투명 |
NaCl | 투명 | 투명 | 투명 | 투명 | 투명 | 투명 |
메티오닌 | 투명 | 투명 | 투명 | 투명 | 혼탁 | 투명 |
글리신 | 투명 | 투명 | 투명 | 투명 | 혼탁 | 투명 |
세린 | 투명 | 투명 | 투명 | 투명 | 혼탁 | 투명 |
프롤린 | 투명 | 투명 | 투명 | 투명 | 혼탁 | 투명 |
리신 | 투명 | 혼탁 | 투명 | 투명 | 혼탁 | 투명 |
MgCl2 | 투명 | 투명 | 투명 | 투명 | 투명 | 투명 |
Tween-20 | 투명 | 투명 | 투명 | 투명 | 투명 | 투명 |
글리세롤 | 투명 | 투명 | 투명 | 투명 | 투명 | 투명 |
에탄올 | 투명 | 투명 | 투명 | 투명 | 투명 | 투명 |
Claims (13)
- 하기를 포함하는 안정한 액상 약학 제형물:약 pH 5.5 내지 약 pH 6.5 의 pH를 갖는 약 20-60mM 숙시네이트 완충액,약 0.01% - 0.1 % 폴리소르베이트,제형물의 등장성삼투압(isotonicity)에 기여하는 장성 조절제(tonicity modifier), 및 50mg/mL 초과의 항체.
- 하기를 포함하는 안정한 액상 약학 제형물:약 pH 5.5 내지 약 pH 6.5 의 pH를 갖는 약 30-70mM 히스티딘 완충액,약 0.01% - 0.1 % 폴리소르베이트,제형물의 등장성삼투압에 기여하는 장성 조절제, 및 50mg/mL 초과의 항체.
- 제 1 항 또는 제 2 항에 있어서, 상기 항체 농도가 100mg/mL을 초과하는 액상 약학 제형물.
- 제 1 항 또는 제 2 항에 있어서, 상기 장성 조절제가 NaCl 또는 MgCl2인 안정한 액상 약학 제형물.
- 제 4 항에 있어서, 상기 NaCl은 75 -150mM인 안정한 액상 약학 제형물.
- 제 4 항에 있어서, 상기 MgCl2가 1 -100mM인 안정한 액상 약학 제형물.
- 제 1 항 또는 제 2 항에 있어서, 상기 pH가 약 6.0 내지 6.5 인 안정한 액상 약학 제형물.
- 제 1 항 또는 제 2 항에 있어서, 상기 폴리소르베이트가 약 0.02 - 0.04%의 농도인 안정한 액상 약학 제형물.
- 제 1 항 또는 제 2 항에 있어서, 0.01 내지 0.5%의 EDTA를 추가로 함유하는 안정한 액상 약학 제형물.
- 제 1 항 또는 제 2 항에 있어서, 상기 제형물이 약 2-8℃에서 1년 이상 안정한, 안정한 액상 약학 제형물.
- 제 1 항 또는 제 2 항에 있어서, 상기 제형물이 약 23-27℃에서 6개월 이상 안정한, 안정한 액상 약학 제형물.
- 하기를 포함하는 액상 약학 제형물:약 pH 5.5 내지 약 pH 6.5 의 pH를 갖는 약 20-60mM 숙시네이트 완충액,약 0.01% - 0.05 % 폴리소르베이트,약 75-150mM 소디움 클로라이드, 및다클리주매브(Daclizumab), 플린토주매브(Flintozumab), HAIL-12 및 HuEP5C7로 이루어지는 군에서 선택된 50mg/mL 초과의 항체.
- 하기를 포함하는 액상 약학 제형물:약 pH 5.5 내지 약 pH 6.5 의 pH를 갖는 약 30-70mM 히스티딘 완충액,약 0.01% - 0.05 % 폴리소르베이트,약 75-150mM 소디움 클로라이드, 및다클리주매브, 플린토주매브, HAIL-12 및 HuEP5C7로 이루어지는 군에서 선택된 50mg/mL 초과의 항체.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33750901P | 2001-11-08 | 2001-11-08 | |
US60/337,509 | 2001-11-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050044365A true KR20050044365A (ko) | 2005-05-12 |
KR100913714B1 KR100913714B1 (ko) | 2009-08-24 |
Family
ID=23320826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047006962A KR100913714B1 (ko) | 2001-11-08 | 2002-11-08 | Igg 항체의 안정한 액상 약학 제형물 |
Country Status (17)
Country | Link |
---|---|
US (3) | US20030138417A1 (ko) |
EP (1) | EP1441589B1 (ko) |
JP (2) | JP5290489B2 (ko) |
KR (1) | KR100913714B1 (ko) |
CN (1) | CN1292655C (ko) |
AT (1) | ATE556591T1 (ko) |
AU (1) | AU2002363339B2 (ko) |
CA (1) | CA2466034C (ko) |
CY (1) | CY2016044I2 (ko) |
DK (1) | DK1441589T3 (ko) |
ES (1) | ES2392073T3 (ko) |
HK (1) | HK1074750A1 (ko) |
IL (2) | IL161677A0 (ko) |
LU (1) | LU93314I2 (ko) |
NZ (1) | NZ532896A (ko) |
PT (1) | PT1441589E (ko) |
WO (1) | WO2003039485A2 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150009593A (ko) * | 2012-05-18 | 2015-01-26 | 제넨테크, 인크. | 고농도 모노클로날 항체 제제 |
Families Citing this family (186)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
IL155002A0 (en) * | 2000-10-12 | 2003-10-31 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
KR100913714B1 (ko) * | 2001-11-08 | 2009-08-24 | 패시트 바이오테크 코포레이션 | Igg 항체의 안정한 액상 약학 제형물 |
US20070148171A1 (en) * | 2002-09-27 | 2007-06-28 | Xencor, Inc. | Optimized anti-CD30 antibodies |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
US20040002451A1 (en) * | 2002-06-20 | 2004-01-01 | Bruce Kerwin | Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing |
EP1551875A4 (en) * | 2002-06-21 | 2006-06-28 | Biogen Idec Inc | TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF |
US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
US20040191243A1 (en) * | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
US20040208870A1 (en) * | 2003-01-30 | 2004-10-21 | Medimmune, Inc. | Stabilized high concentration anti-integrin alphanubeta3 antibody formulations |
US20040208869A1 (en) * | 2003-01-30 | 2004-10-21 | Medimmune, Inc. | Uses of anti-integrin alphanubeta3 antibody formulations |
WO2004075913A1 (ja) | 2003-02-28 | 2004-09-10 | Chugai Seiyaku Kabushiki Kaisha | タンパク質含有安定化製剤 |
US20050158303A1 (en) * | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
RU2332986C2 (ru) * | 2003-04-04 | 2008-09-10 | Дженентек, Инк. | Высококонцентрированные композиции антител и белков |
PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
DK1691833T3 (da) * | 2003-11-28 | 2010-05-03 | Micromet Ag | Præparater der omfatter polypeptider |
US20050136055A1 (en) * | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
DK2177537T3 (da) | 2004-01-09 | 2011-12-12 | Pfizer | Antistoffer til MAdCAM |
US20060008415A1 (en) * | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
WO2006066089A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
AR052469A1 (es) * | 2005-01-28 | 2007-03-21 | Wyeth Corp | Formulaciones liquidas estabilizadas de polipeptido |
AU2014240252B2 (en) * | 2005-03-08 | 2016-10-06 | Pfizer Products Inc | Anti-CTLA-4 Antibody Compositions |
AU2012200203B2 (en) * | 2005-03-08 | 2014-07-03 | Pfizer Products Inc. | Anti-CTLA-4 Antibody Compositions |
WO2006096490A2 (en) * | 2005-03-08 | 2006-09-14 | Pharmacia & Upjohn Company Llc | ANTI-MAdCAM ANTIBODY COMPOSITIONS |
DK1861116T3 (en) | 2005-03-25 | 2015-11-09 | Regeneron Pharma | VEGF antagonist formulations |
MX2007014148A (es) * | 2005-05-19 | 2008-01-11 | Amgen Inc | Composiciones y metodos para incrementar la estabilidad de anticuerpos. |
EP1909831A4 (en) | 2005-06-14 | 2013-02-20 | Amgen Inc | PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS |
CA2613512A1 (en) * | 2005-06-23 | 2007-01-04 | Medimmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
WO2007016562A2 (en) * | 2005-07-29 | 2007-02-08 | Amgen Inc. | Formulations that inhibit protein aggregation |
CA2615122A1 (en) * | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
AR057807A1 (es) * | 2005-09-12 | 2007-12-19 | Novimmune Sa | Formulaciones de anticuerpo anti-cd3 |
KR101105871B1 (ko) * | 2005-09-27 | 2012-01-16 | 주식회사 엘지생명과학 | 인 난포자극호르몬의 안정한 용액 제형 |
AU2006302254B2 (en) | 2005-10-06 | 2011-05-26 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US7390786B2 (en) * | 2005-12-21 | 2008-06-24 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
US8569278B2 (en) | 2006-01-25 | 2013-10-29 | Taro Pharmaceuticals North America, Inc. | Anti-histamine compositions and use thereof |
AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
SG170837A1 (en) | 2006-04-05 | 2011-05-30 | Abbott Biotech Ltd | Antibody purification |
AU2007239679B2 (en) | 2006-04-13 | 2012-10-11 | Chugai Seiyaku Kabushiki Kaisha | Taurine transporter gene |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
EA018301B1 (ru) | 2006-04-21 | 2013-07-30 | Новартис Аг | Фармацевтические композиции, содержащие антагонистическое моноклональное антитело к cd40, и их применение |
TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
AU2016204760A1 (en) * | 2006-04-26 | 2016-07-28 | Wyeth Llc | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
AU2014268186C1 (en) * | 2006-04-26 | 2017-12-07 | Wyeth Llc | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
EP2029103A2 (en) | 2006-06-16 | 2009-03-04 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
AU2012200284B2 (en) * | 2006-10-06 | 2014-03-06 | Amgen Inc. | Stable Antibody Formulations |
US20080112953A1 (en) * | 2006-10-06 | 2008-05-15 | Amgen Inc. | Stable formulations |
EP2094247B1 (en) * | 2006-10-20 | 2022-06-29 | Amgen Inc. | Stable polypeptide formulations |
JP5577098B2 (ja) * | 2006-12-21 | 2014-08-20 | アムジエン・インコーポレーテツド | ポリペプチドを含有する安定な緩衝化された製剤 |
JP5635260B2 (ja) | 2007-03-15 | 2014-12-03 | 中外製薬株式会社 | ポリペプチドの製造方法 |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
WO2009009406A1 (en) * | 2007-07-06 | 2009-01-15 | Smithkline Beecham Corporation | Antibody formulations |
PL2182983T3 (pl) | 2007-07-27 | 2014-10-31 | Janssen Alzheimer Immunotherap | Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta |
BRPI0815036B1 (pt) | 2007-08-07 | 2022-09-20 | Chugai Seiyaku Kabushiki Kaisha | Métodos para produção de um polipeptídeo e para preparação de um produto farmacêutico |
SG10201605394SA (en) | 2007-09-26 | 2016-08-30 | Chugai Pharmaceutical Co Ltd | Modified Antibody Constant Region |
EP3689912A1 (en) | 2007-09-26 | 2020-08-05 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
CN101939425B (zh) | 2007-09-26 | 2014-05-14 | 中外制药株式会社 | 抗il-6受体抗体 |
US9802993B2 (en) | 2007-10-15 | 2017-10-31 | Chugai Seiyaku Kabushiki Kaisha | Method for producing a cell for protein production by treating a cell overexpressing a taurine transporter with methotrexate |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
RU2494148C2 (ru) | 2007-10-24 | 2013-09-27 | Чугаи Сейяку Кабусики Кайся | Клетка для получения гетеропротеинов и способ получения на ее основе |
EP2219602A1 (en) * | 2007-11-15 | 2010-08-25 | Amgen, Inc | Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
CA2710775A1 (en) * | 2007-12-28 | 2009-07-09 | Bioinvent International Ab | Formulation |
EP2328607A1 (en) | 2008-07-16 | 2011-06-08 | Arecor Limited | Stable formulation of a therapeutic protein |
WO2010089522A1 (en) * | 2009-07-16 | 2010-08-12 | Arecor Limited | Stable formulation of a therapeutic protein |
AU2009294680A1 (en) | 2008-09-19 | 2010-03-25 | F. Hoffmann-La Roche Ag | Novel antibody formulation |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
CN102301235B (zh) * | 2008-11-28 | 2014-11-19 | Abbvie公司 | 稳定的抗体组合物和用于稳定其的方法 |
EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
WO2010100135A1 (en) | 2009-03-05 | 2010-09-10 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
CA2754528A1 (en) * | 2009-03-06 | 2010-09-10 | Genetech, Inc. | Antibody formulation |
SG174606A1 (en) * | 2009-03-30 | 2011-11-28 | Hoffmann La Roche | A method for avoiding glass fogging |
EP2423309B1 (en) | 2009-04-22 | 2018-01-03 | Chugai Seiyaku Kabushiki Kaisha | A method for producing a cell capable of high-yield production of heteroproteins |
JP2012526121A (ja) * | 2009-05-04 | 2012-10-25 | アボツト・バイオテクノロジー・リミテツド | ヒト抗tnfアルファ抗体の安定した高蛋白質濃度製剤 |
CA2765220A1 (en) * | 2009-07-14 | 2011-01-20 | Biogen Idec Ma Inc. | Methods for inhibiting yellow color and peroxide formation in a composition |
EP2473851A1 (en) | 2009-08-31 | 2012-07-11 | Abbott Biotherapeutics Corp. | Use of an immunoregulatory nk cell population for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients |
EP2473527B1 (en) * | 2009-09-03 | 2016-11-30 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
US8821879B2 (en) | 2009-09-04 | 2014-09-02 | Xoma Technology Ltd. | Anti-botulism antibody coformulations |
WO2011028962A1 (en) * | 2009-09-04 | 2011-03-10 | Xoma Technology Ltd. | Antibody coformulations |
CA2774286A1 (en) | 2009-10-30 | 2011-05-05 | Abbott Biotherapeutics Corp. | Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients |
JP2013515754A (ja) * | 2009-12-29 | 2013-05-09 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 新規な抗体製剤 |
RS57870B1 (sr) | 2010-01-06 | 2018-12-31 | Dyax Corp | Proteini koji vezuju kalikrein plazme |
US20120294866A1 (en) * | 2010-01-19 | 2012-11-22 | F. Hoffmann-La Roche Ag | Pharmaceutical formulation for proteins |
AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
NZ602115A (en) | 2010-03-01 | 2014-12-24 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
US9956165B2 (en) | 2010-03-01 | 2018-05-01 | Cytodyn Inc. | Concentrated protein formulations and uses thereof |
HUE048398T2 (hu) | 2010-06-04 | 2020-07-28 | Wyeth Llc | Vakcinakészítmények |
FR2961107B1 (fr) * | 2010-06-15 | 2012-07-27 | Lab Francais Du Fractionnement | Composition d'immunoglobulines humaines stabilisee |
SG188487A1 (en) * | 2010-09-17 | 2013-05-31 | Baxter Int | Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph |
JO3400B1 (ar) | 2010-09-30 | 2019-10-20 | Ferring Bv | مركب صيدلاني من كاربيتوسين |
CA3017116A1 (en) | 2010-11-04 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Anti-il-23 antibodies |
MX344727B (es) | 2010-11-11 | 2017-01-05 | Abbvie Biotechnology Ltd | Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas. |
EP2471554A1 (en) * | 2010-12-28 | 2012-07-04 | Hexal AG | Pharmaceutical formulation comprising a biopharmaceutical drug |
KR102107695B1 (ko) | 2011-01-06 | 2020-05-07 | 다이액스 코포레이션 | 혈장 칼리크레인 결합 단백질 |
KR20210030510A (ko) | 2011-01-13 | 2021-03-17 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
EP2697369B1 (en) | 2011-03-25 | 2018-06-27 | F.Hoffmann-La Roche Ag | Novel protein purification methods |
UY34105A (es) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
US20130004484A1 (en) * | 2011-06-30 | 2013-01-03 | Genentech, Inc. | Anti-c-met antibody formulations |
EA037797B1 (ru) | 2011-10-25 | 2021-05-21 | Протена Байосайенсиз Лимитед | Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения |
US10316095B2 (en) * | 2012-02-16 | 2019-06-11 | Santarus, Inc. | Antibody formulations |
ES2908474T3 (es) * | 2012-05-03 | 2022-04-29 | Boehringer Ingelheim Int | Anticuerpos anti-IL-23p19 |
US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
EP2869817A4 (en) * | 2012-07-09 | 2016-04-06 | Coherus Biosciences Inc | STABLE AQUEOUS FORMULATIONS OF ETANERCEPT |
FR2994390B1 (fr) | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
PE20191815A1 (es) | 2012-09-07 | 2019-12-27 | Coherus Biosciences Inc | Formulaciones acuosas estables de adalimumab |
EP2727602A1 (en) | 2012-10-31 | 2014-05-07 | Takeda GmbH | Method for preparation of a high concentration liquid formulation of an antibody |
UA117466C2 (uk) * | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
JP2016514690A (ja) | 2013-03-15 | 2016-05-23 | アッヴィ バイオテクノロジー リミテッド | 抗cd25抗体およびそれらの使用 |
SG11201506499YA (en) | 2013-03-15 | 2015-09-29 | Glaxosmithkline Ip No 2 Ltd | Low concentration antibody formulations |
EP3216804A3 (en) | 2013-03-15 | 2017-12-20 | AbbVie Biotechnology Ltd. | Anti-cd25 antibodies and their uses |
WO2014152232A2 (en) | 2013-03-15 | 2014-09-25 | Dyax Corp. | Anti-plasma kallikrein antibodies |
CN103217525B (zh) * | 2013-03-21 | 2015-04-29 | 上海执诚生物科技股份有限公司 | 一种含有提高胱抑素c胶乳包被抗体的稳定性的组合物、稳定剂及其制备方法和用途 |
KR20140119396A (ko) | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
US10745475B2 (en) | 2013-08-30 | 2020-08-18 | Takeda Gmbh | Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics |
KR102372245B1 (ko) | 2013-11-21 | 2022-03-08 | 젠맵 에이/에스 | 항체-약물 접합체 동결건조 제제 |
EA038532B1 (ru) | 2014-01-21 | 2021-09-10 | Такеда Фармасьютикал Компани Лимитед | Способ лечения наследственного ангионевротического отека (hae) |
BR112016022318A2 (pt) | 2014-03-27 | 2017-10-31 | Dyax Corp | método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo |
BR112016025126B1 (pt) * | 2014-05-07 | 2024-02-15 | Takeda Pharmaceutical Company Limited | Composição aquosa compreendendo anticorpo neutralizante de gmcsf, e uso da mesma |
TWI694836B (zh) * | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
WO2015196091A1 (en) | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
EP3157947A1 (en) | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
EP3157942B1 (en) | 2014-06-23 | 2020-06-17 | Novartis AG | Site specific protein modifications |
EP3708679A1 (en) | 2014-07-24 | 2020-09-16 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
TWI711629B (zh) | 2014-09-03 | 2020-12-01 | 德商包林格因蓋爾漢國際股份有限公司 | 靶向IL-23A與TNF-α之化合物及其用途 |
EP3209682B1 (en) | 2014-10-24 | 2020-12-30 | Merck Sharp & Dohme Corp. | Co-agonists of the glucagon and glp-1 receptors |
MA51554A (fr) | 2014-11-07 | 2020-11-18 | Sesen Bio Inc | Anticorps il-6 améliorés |
AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
MA41580A (fr) | 2015-01-23 | 2017-11-29 | Novartis Ag | Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée |
US11091543B2 (en) | 2015-05-07 | 2021-08-17 | Swedish Orphan Biovitrum Ag | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
EA037532B1 (ru) | 2015-05-07 | 2021-04-08 | Новиммун Са | Способы и композиции для диагностики и лечения заболеваний у пациентов, имеющих повышенные уровни cxcl9 и других биомаркеров |
AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
ES2964640T3 (es) | 2015-08-13 | 2024-04-08 | Amgen Inc | Filtración en profundidad cargada de proteínas de unión al antígeno |
US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
AU2016364817B2 (en) | 2015-12-03 | 2020-05-07 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
US20170157215A1 (en) | 2015-12-04 | 2017-06-08 | Jomoco, Corp. | Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates |
BR112018011622A2 (pt) | 2015-12-11 | 2018-11-27 | Dyax Corp | método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae |
WO2017109706A1 (en) | 2015-12-22 | 2017-06-29 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
SG11201805534TA (en) | 2016-01-13 | 2018-07-30 | Genmab As | Formulation for antibody and drug conjugate thereof |
WO2017147293A1 (en) * | 2016-02-23 | 2017-08-31 | Eleven Biotherapeutics, Inc. | Il-6 antagonist formulations and uses thereof |
US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
WO2018027195A1 (en) * | 2016-08-05 | 2018-02-08 | Abbvie Biotherapeutics Inc. | Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same |
BR112019007858A2 (pt) | 2016-10-21 | 2019-07-02 | Amgen Inc | formulações farmacêuticas e métodos para produzir as mesmas |
KR20180046888A (ko) | 2016-10-28 | 2018-05-09 | (주)셀트리온 | 안정한 약제학적 제제 |
US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
WO2018156367A1 (en) * | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
GB201703062D0 (en) * | 2017-02-24 | 2017-04-12 | Arecor Ltd | Stabilized antibody protein solutions |
US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
TW202228779A (zh) * | 2017-03-01 | 2022-08-01 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
EP3372242A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
EP3372241A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
JP7179717B2 (ja) * | 2017-03-31 | 2022-11-29 | Meiji Seikaファルマ株式会社 | 水性製剤及び注射器入り水性製剤、並びに、抗体タンパク脱凝集剤及び抗体タンパク脱凝集方法 |
CN110831621A (zh) * | 2017-04-18 | 2020-02-21 | 雷迪博士实验室有限公司 | 稳定的液体药物组合物 |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
US11845798B2 (en) | 2017-05-02 | 2023-12-19 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
MX2019013751A (es) * | 2017-05-16 | 2020-01-15 | Jiangsu Hengrui Medicine Co | Composicion farmaceutica de anticuerpos del ligando 1 de muerte programada y su uso. |
AR112336A1 (es) | 2017-07-14 | 2019-10-16 | Pfizer | ANTICUERPOS CONTRA MAdCAM |
JP2020532562A (ja) | 2017-09-05 | 2020-11-12 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 生物学的製剤の粘度を低下させるための化合物 |
MA50174A (fr) * | 2017-09-18 | 2020-07-29 | Amgen Inc | Formules de protéines de fusion vegfr-fc |
IL307483A (en) | 2017-12-22 | 2023-12-01 | Novartis Ag | Methods for treating metabolic disorders with FGF21 variants |
WO2019217927A1 (en) | 2018-05-10 | 2019-11-14 | Regeneron Pharmaceuticals, Inc. | High concentration vegf receptor fusion protein containing formulations |
US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
WO2020109978A1 (en) | 2018-11-26 | 2020-06-04 | Novartis Ag | Lpl-gpihbp1 fusion polypeptides |
KR20210096640A (ko) * | 2018-11-29 | 2021-08-05 | 하버 바이오메드 테라푸틱스 리미티드 | 항-pd-l1 항체 제제 |
EP3914282A1 (en) | 2019-01-25 | 2021-12-01 | Ospedale San Raffaele S.r.l. | Inhibitor of dux4 and uses thereof |
EP3996740A4 (en) * | 2019-07-12 | 2023-07-05 | Contrafect Corporation | THERAPEUTIC PROTEIN FORMULATIONS INCLUDING ANTIBODIES AND THEIR USES |
GB201913697D0 (en) | 2019-09-23 | 2019-11-06 | King S College London | DAP10/DAP12 fusion polypeptides |
JP2023512446A (ja) * | 2020-01-13 | 2023-03-27 | アプティーボ リサーチ アンド デベロップメント エルエルシー | 治療的タンパク質の薬物送達システム構成要素への吸着を防ぐ方法および組成物 |
GB202003277D0 (en) | 2020-03-06 | 2020-04-22 | King S College London | Therapeutic agents |
CN115605185A (zh) * | 2020-05-19 | 2023-01-13 | 豪夫迈·罗氏有限公司(Ch) | 螯合剂用于防止胃肠外蛋白质溶液中形成可见颗粒的用途 |
GB202007655D0 (en) | 2020-05-22 | 2020-07-08 | King S College London | Chimeric nkg2d protein |
WO2022200442A1 (en) | 2021-03-23 | 2022-09-29 | King's College London | Compositions comprising nkg2d, cxcr2, and dap10/dap12 fusion polypeptides and methods of use thereof |
GB202214120D0 (en) | 2022-09-27 | 2022-11-09 | King S College London | Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5091178A (en) * | 1986-02-21 | 1992-02-25 | Oncogen | Tumor therapy with biologically active anti-tumor antibodies |
EP0417193B1 (en) | 1988-05-27 | 1993-08-04 | Centocor, Inc. | Freeze-dried formulation for antibody products |
JPH04502914A (ja) * | 1988-12-15 | 1992-05-28 | セントユール,インコーポレイテッド | 免疫グロブリンを可溶化するための塩基性アミノ酸の使用 |
EP0465513A1 (en) | 1989-03-27 | 1992-01-15 | Centocor, Inc. | FORMULATIONS FOR STABILIZING OF IgM ANTIBODIES |
US6165467A (en) * | 1991-07-20 | 2000-12-26 | Yoshihide Hagiwara | Stabilized human monoclonal antibody preparation |
WO1996024369A1 (en) * | 1995-02-06 | 1996-08-15 | Genetics Institute, Inc. | Formulations for il-12 |
CA2226575C (en) * | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
GB9610992D0 (en) * | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
EP0852951A1 (de) * | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
DE69810481T2 (de) * | 1997-06-13 | 2003-09-25 | Genentech Inc | Stabilisierte antikörperformulierung |
US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
IL145134A0 (en) | 1999-03-25 | 2002-06-30 | Knoll Gmbh | Human antibodies that bind human il-12 and methods for producing |
US6914128B1 (en) * | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
IL155002A0 (en) * | 2000-10-12 | 2003-10-31 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
KR100913714B1 (ko) * | 2001-11-08 | 2009-08-24 | 패시트 바이오테크 코포레이션 | Igg 항체의 안정한 액상 약학 제형물 |
-
2002
- 2002-11-08 KR KR1020047006962A patent/KR100913714B1/ko active IP Right Grant
- 2002-11-08 WO PCT/US2002/036093 patent/WO2003039485A2/en active Application Filing
- 2002-11-08 US US10/291,528 patent/US20030138417A1/en not_active Abandoned
- 2002-11-08 NZ NZ532896A patent/NZ532896A/en not_active IP Right Cessation
- 2002-11-08 ES ES02802895T patent/ES2392073T3/es not_active Expired - Lifetime
- 2002-11-08 CA CA2466034A patent/CA2466034C/en not_active Expired - Lifetime
- 2002-11-08 IL IL16167702A patent/IL161677A0/xx unknown
- 2002-11-08 CN CNB028267273A patent/CN1292655C/zh not_active Expired - Fee Related
- 2002-11-08 AU AU2002363339A patent/AU2002363339B2/en not_active Ceased
- 2002-11-08 DK DK02802895.9T patent/DK1441589T3/da active
- 2002-11-08 PT PT02802895T patent/PT1441589E/pt unknown
- 2002-11-08 JP JP2003541777A patent/JP5290489B2/ja not_active Expired - Fee Related
- 2002-11-08 AT AT02802895T patent/ATE556591T1/de active
- 2002-11-08 EP EP02802895A patent/EP1441589B1/en not_active Expired - Lifetime
-
2004
- 2004-04-29 IL IL161677A patent/IL161677A/en active IP Right Grant
-
2005
- 2005-08-17 HK HK05107139A patent/HK1074750A1/xx not_active IP Right Cessation
-
2010
- 2010-11-24 US US12/954,512 patent/US20110070231A1/en not_active Abandoned
- 2010-12-10 JP JP2010276222A patent/JP2011068675A/ja active Pending
-
2011
- 2011-09-06 US US13/226,372 patent/US8465739B2/en not_active Expired - Lifetime
-
2016
- 2016-11-17 LU LU93314C patent/LU93314I2/fr unknown
- 2016-12-09 CY CY2016044C patent/CY2016044I2/el unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150009593A (ko) * | 2012-05-18 | 2015-01-26 | 제넨테크, 인크. | 고농도 모노클로날 항체 제제 |
Also Published As
Publication number | Publication date |
---|---|
JP2005508981A (ja) | 2005-04-07 |
DK1441589T3 (da) | 2012-08-06 |
WO2003039485A2 (en) | 2003-05-15 |
JP5290489B2 (ja) | 2013-09-18 |
US20110318343A1 (en) | 2011-12-29 |
EP1441589A2 (en) | 2004-08-04 |
AU2002363339B2 (en) | 2008-02-07 |
WO2003039485A3 (en) | 2004-02-12 |
IL161677A0 (en) | 2004-09-27 |
KR100913714B1 (ko) | 2009-08-24 |
US8465739B2 (en) | 2013-06-18 |
CN1292655C (zh) | 2007-01-03 |
EP1441589A4 (en) | 2007-07-04 |
CN1612689A (zh) | 2005-05-04 |
IL161677A (en) | 2010-06-16 |
CA2466034C (en) | 2012-12-18 |
ATE556591T1 (de) | 2012-05-15 |
US20110070231A1 (en) | 2011-03-24 |
HK1074750A1 (en) | 2005-11-25 |
JP2011068675A (ja) | 2011-04-07 |
PT1441589E (pt) | 2012-08-13 |
ES2392073T3 (es) | 2012-12-04 |
EP1441589B1 (en) | 2012-05-09 |
CY2016044I1 (el) | 2017-07-12 |
CA2466034A1 (en) | 2003-05-15 |
CY2016044I2 (el) | 2017-07-12 |
LU93314I2 (ko) | 2019-11-20 |
NZ532896A (en) | 2007-08-31 |
US20030138417A1 (en) | 2003-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100913714B1 (ko) | Igg 항체의 안정한 액상 약학 제형물 | |
AU2002363339A1 (en) | Stable liquid pharmaceutical formulation of IGG antibodies | |
US8298530B2 (en) | Stable lyophilized pharmaceutical formulation of IgG antibodies | |
EP2568960B1 (en) | Liquid formulation of polypeptides containing an fc domain of an immunoglobulin | |
AU2003211991B2 (en) | Antibody-containing solution formulations | |
WO2004039337A2 (en) | Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization | |
US20210188964A1 (en) | Solution Formulations of Engineered Anti-IL-23p19 Antibodies | |
US20110158987A1 (en) | Novel antibody formulation | |
US20150329628A1 (en) | Liquid formulations for an anti-tnf alpha antibody | |
AU2004216298A1 (en) | Stabilized protein-containing formulations | |
KR102106914B1 (ko) | Gm-csf를 중화하는 화합물을 포함하는 액체 제제 | |
US20040009168A1 (en) | Multidose antibody formulation | |
US20040170632A1 (en) | Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan | |
CN111375057A (zh) | 一种包含抗Her2单克隆抗体的药物配制剂 | |
EP4070817A1 (en) | Liquid preparation containing anti-il-17 antibody | |
EP3808777A1 (en) | Stable liquid antibody formulations | |
CN116059342A (zh) | 包含重组全人源抗ifnar1单克隆抗体的液体制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
N231 | Notification of change of applicant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120727 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20130729 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140730 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20160629 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170629 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20180628 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20190624 Year of fee payment: 11 |